Comparison of Ischemic Side Effects of Levosimendan and Dobutamine with Integrated Backscatter Analysis

Basit Öğe Kaydı
dc.contributor.authorDuygu, Hamza
dc.contributor.authorNalbantgil, Sanern
dc.contributor.authorZoghi, Mehdi
dc.contributor.authorOzerkan, Filiz
dc.contributor.authorYildiz, Ahmet
dc.contributor.authorAkilli, Azem
dc.contributor.authorAkin, Mustafa
dc.date.accessioned2019-10-27T20:52:35Z
dc.date.available2019-10-27T20:52:35Z
dc.date.issued2009
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: Levosimendan improves cardiac contractility without increasing oxygen consumption. However, its effects on ischemia were not supported with the utilization of a noninvasive parameter of myocardial characterization. Hypothesis: The changes observed in integrated backscatter (IBS) may be reflective of change in myocardial ischemia. In this study, the effect of levosimendan on ischemia detected by IBS was evaluated in patients with ischemic heart failure (HF). Methods: Patients who had LVEF <40% and NYHA III-IV symptoms of HF were included in this study. Patients were randomized to levosimendan (n = 21), or to dobutamine (n = 25) groups. The cyclic variation of integrated backscatter (CVIBS) was determined as the difference between the maximal and minimal values in a cardiac cycle.. average of three consecutive beats. CVIBS was taken from the mid-anteroseptal, mid-inferior, and mid-posterolateral areas of the parasternal short axis images before the drug administration and at the end of the 24-hour infusion period. Results: Baseline characteristics and concomitant medications were similar in both groups. A significant reduction in CVIBS was detected in anteroseptal (7.6 +/- 1.4 dB versus 5.9 +/- 0.8 dB, p = 0.01), inferior watt (7.4 +/- 0.8 dB versus 6.7 +/- 1.5 dB, P = 0.03), and posterolateral wall (9.0 +/- 1.2 dB versus 8.2 +/- 0.6 dB, P = 0.04) after dobutamine administration, while no significant changes were observed in the levosimendan group in all walls. Conclusions: Unlike dobutamine, levosimendan may not induce myocardial ischemia as shown by CVIBS at commonly used dosages in the setting of decompensated HF without active ischemia.en_US
dc.identifier.doi10.1002/clc.20313en_US
dc.identifier.endpage192en_US
dc.identifier.issn0160-9289
dc.identifier.issue4en_US
dc.identifier.pmid19353707en_US
dc.identifier.startpage187en_US
dc.identifier.urihttps://doi.org/10.1002/clc.20313
dc.identifier.urihttps://hdl.handle.net/11454/43247
dc.identifier.volume32en_US
dc.identifier.wosWOS:000265195500005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherJohn Wiley & Sons Incen_US
dc.relation.ispartofClinical Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleComparison of Ischemic Side Effects of Levosimendan and Dobutamine with Integrated Backscatter Analysisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu